FAQ

Clinical trials are designed to evaluate new treatments, including their safety and efficacy. They are mandatory before approval and commercialization of new treatments.

Each clinical trial is conducted according to a protocol defined upstream and validated by the health authorities and various committees to protect the interest of patients. To be included in a clinical trial, the patient must meet a number of criteria that are specific to each trial and contained in the protocol.

The risks and benefits of participating in a clinical trial are described in the research protocol and the informed consent document. The medical team also explains them to the patient, who is free to ask questions.

Participating in a clinical trial gives access to an innovative treatment before it is potentially widely available. Clinical trials also provide a specific frame of care and support, as well as an appropriate and rigorous follow-up during and after the completion of the treatment.

As with any treatment, drug candidates used in clinical trials can cause side effects. In some clinical trials, it is also possible to be part of the control group and not receive innovative treatment.

First, the patients should discuss this topic with their physician and oncologist. He can then get closer to the doctors in charge of the clinical trial (investigator).

When possible, Transgene provides the clinical trial number (NCT) of the www.clinicaltrials.gov database, that lists the sites where studies are active (refer to the “products” page on the website).

Transgene cannot respond to inquiries about participation in its clinical trials. Patients should discuss treatment options with their physician who, if relevant, may connect them with the doctors in charge of clinical trials.

Transgene’s position on Early Access to Investigational Medicines can be accessed here.

More information on the website of the French National Cancer Institute (INCa) website or on the US National Cancer Institute website.